These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
509 related articles for article (PubMed ID: 30351177)
1. Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys. Nagai Y; Oitate M; Shiozawa H; Ando O Xenobiotica; 2019 Sep; 49(9):1086-1096. PubMed ID: 30351177 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Okamoto H; Oitate M; Hagihara K; Shiozawa H; Furuta Y; Ogitani Y; Kuga H Xenobiotica; 2020 Oct; 50(10):1242-1250. PubMed ID: 32306807 [TBL] [Abstract][Full Text] [Related]
3. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Takegawa N; Nonagase Y; Yonesaka K; Sakai K; Maenishi O; Ogitani Y; Tamura T; Nishio K; Nakagawa K; Tsurutani J Int J Cancer; 2017 Oct; 141(8):1682-1689. PubMed ID: 28677116 [TBL] [Abstract][Full Text] [Related]
4. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974 [TBL] [Abstract][Full Text] [Related]
5. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201 [TBL] [Abstract][Full Text] [Related]
6. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997 [TBL] [Abstract][Full Text] [Related]
7. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model. Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841 [TBL] [Abstract][Full Text] [Related]
8. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Kumagai K; Aida T; Tsuchiya Y; Kishino Y; Kai K; Mori K Cancer Sci; 2020 Dec; 111(12):4636-4645. PubMed ID: 33051938 [TBL] [Abstract][Full Text] [Related]
9. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803 [TBL] [Abstract][Full Text] [Related]
10. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Shitara K; Iwata H; Takahashi S; Tamura K; Park H; Modi S; Tsurutani J; Kadowaki S; Yamaguchi K; Iwasa S; Saito K; Fujisaki Y; Sugihara M; Shahidi J; Doi T Lancet Oncol; 2019 Jun; 20(6):827-836. PubMed ID: 31047804 [TBL] [Abstract][Full Text] [Related]
11. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805 [TBL] [Abstract][Full Text] [Related]
12. Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. Suzuki M; Yagishita S; Sugihara K; Ogitani Y; Nishikawa T; Ohuchi M; Teishikata T; Jikoh T; Yatabe Y; Yonemori K; Tamura K; Hasegawa K; Hamada A Clin Cancer Res; 2021 Jul; 27(14):3970-3979. PubMed ID: 33980613 [TBL] [Abstract][Full Text] [Related]
13. Transition of average drug-to-antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography-tandem mass spectrometry. Habara H; Okamoto H; Nagai Y; Oitate M; Takakusa H; Watanabe N Biopharm Drug Dispos; 2023 Oct; 44(5):380-384. PubMed ID: 37534716 [TBL] [Abstract][Full Text] [Related]
14. [Development of New ADC Technology with Topoisomerase I Inhibitor]. Agatsuma T Yakugaku Zasshi; 2017; 137(5):545-550. PubMed ID: 28458286 [TBL] [Abstract][Full Text] [Related]
15. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Mauricio D; Bellone S; Mutlu L; McNamara B; Manavella DD; Demirkiran C; Verzosa MSZ; Buza N; Hui P; Hartwich TMP; Harold J; Yang-Hartwich Y; Zipponi M; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Santin AD Gynecol Oncol; 2023 Mar; 170():38-45. PubMed ID: 36610380 [TBL] [Abstract][Full Text] [Related]
16. Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. Andrikopoulou A; Zografos E; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F Clin Breast Cancer; 2021 Jun; 21(3):e212-e219. PubMed ID: 32917537 [TBL] [Abstract][Full Text] [Related]
17. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. Iwata TN; Sugihara K; Wada T; Agatsuma T PLoS One; 2019; 14(10):e0222280. PubMed ID: 31574081 [TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Patritumab Deruxtecan in Patients With Solid Tumors. Lu Y; Shimizu S; Sawamura R; Tajima N; He L; Lee M; Abutarif M; Shi R J Clin Pharmacol; 2023 Jan; 63(1):77-90. PubMed ID: 36053771 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. Takahashi S; Karayama M; Takahashi M; Watanabe J; Minami H; Yamamoto N; Kinoshita I; Lin CC; Im YH; Achiwa I; Kamiyama E; Okuda Y; Lee C; Bang YJ Clin Cancer Res; 2021 Nov; 27(21):5771-5780. PubMed ID: 34426442 [TBL] [Abstract][Full Text] [Related]
20. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. Modi S; Park H; Murthy RK; Iwata H; Tamura K; Tsurutani J; Moreno-Aspitia A; Doi T; Sagara Y; Redfern C; Krop IE; Lee C; Fujisaki Y; Sugihara M; Zhang L; Shahidi J; Takahashi S J Clin Oncol; 2020 Jun; 38(17):1887-1896. PubMed ID: 32058843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]